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Abstract
Background:  Oxidative stress, resulting in a marked increase in the level of oxygen free radicals
(OFR), has been implicated in the etiology of diabetic neuropathy (DN). Antioxidant enzymes may
protect against the rapid onset and progression of DN, by reducing the excess of OFR and
peroxide. Mutations and polymorphisms in the genes encoding such enzymes may therefore result
in predisposition to DN. We investigated the role of genes encoding two antioxidant enzymes,
mitochondrial (Mn-SOD) and extracellular (EC-SOD) superoxide dismutase, in DN pathogenesis
in a Russian population. We studied Ala(-9)Val and Ile58Thr polymorphisms of the Mn-SOD gene
and Arg213Gly dimorphism of the EC-SOD gene in type 1 diabetic patients with (n = 82) and
without DN (n = 84).
Results:  We developed and used a new polymerase chain reaction (PCR) assays for rapid
detection of polymorphisms. These assays involved the use of mismatch PCR primers to create
restriction sites in the amplified product only in presence of the polymorphic base. The PCR
product was than digested with BshTI, Eco32I or Eco52I to detect Ala(-9)Val, Ile58Thr or Arg213Gly
polymorphic site respectively. The frequencies of the Ala allele (50.6% vs. 68.5%, p < 0.002) and
the Ala/Ala genotype (17.1% vs. 39.3%, p < 0.005) of the Mn-SOD gene were significantly lower in
DN patients than in diabetic subjects without DN. In contrast, the Val allele (49.4% vs. 31.5%, p <
0.002) and the Val/Val genotype (15.9% vs. 2.4%, p < 0.01) were significantly more frequent in the
DN patients than in the control group.
Conclusions:  Ala(-9)Val substitution in the Mn-SOD gene was associated with DN in a Russian
population
Background
Oxidative stress has been implicated in the etiology of
long-term diabetic complications, including peripheral
neuropathy [1]. Oxygen free radicals (OFR) may damage
neurons by causing nerve lipid peroxidation, the break-
down of mitochondrial DNA and inhibition of the respi-
ratory chain, and the cross-linking of the neurofilament
protein [2–4]. Treatment with antioxidants (e.g. probu-
col, alpha-lipoic acid) decreases lipid peroxidation and
oxidative stress in neural tissues and improves the con-
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ropathy [5, 6].
Antioxidant enzyme activity is low in peripheral nerves
and even lower in diabetic nerves, possibly due non-en-
zymatic glycation and autooxidation of the glycated pro-
tein [7, 8]. Antioxidant enzymes may protect against the
rapid onset and progression of diabetic neuropathy (DN)
by reducing the excess of both OFR and peroxide. De-
fects and mutations in the genes encoding these enzymes
may therefore lead to suspectibility to DN.
Superoxide dismutase (SOD) is the key antioxidant en-
zyme involved in the detoxication of superoxide radicals.
SOD is a metalloprotein and its manganese form (Mn-
SOD) is present in mitochondria. Two other forms con-
taining cooper and zinc (CuZn) have cytoplasmic or ex-
tracellular (EC-SOD) location.
An alanine (GCT) to valine (GTT) substitution at position
-9 in the signal peptide of human Mn-SOD has been
shown to change the structural conformation of the mi-
tochondrial targeting sequence of the enzyme. This sub-
stitution may lead to misdirected intracellular
trafficking, followed by changes in Mn-SOD activity in
the mitochondria [9, 10]. Associations have been found
between the Ala(-9)Val dimorphism in the SOD2 gene
and such human neurodegenerative and ageing disor-
ders as Parkinson's disease [9], tardive dyskinesia [11],
sporadic motor neuron disease [12], and nonfamilial idi-
opathic dilated cardiomyopathy [13].
The Ile58Thr amino acid exchange destabilizes the tetra-
meric interface of Mn-SOD and reduces its enzymatic ac-
tivity [14]. This finding suggests that the Ile58Thr
polymorphism may be associated with neurodegenera-
tive diseases involving a decrease in Mn-SOD levels [15].
However, no association between the Ile58Thr polymor-
phism and Parkinson's disease was found in German pa-
tients [16].
Extracellular superoxide dismutase (EC-SOD) has an
amino acid substitution Arg213Gly in the heparin-bind-
ing domain [17]. The glycine variant of the enzyme is re-
sponsible for high EC-SOD levels in serum [18, 19] that
are correlated with a decrese in nitric oxide production in
epithelial cells [20] and various other metabolic cardio-
vascular risk factors [21]. A relationship was found be-
tween the Arg213Gly dimorphism and familial
amyloidotic (non-diabetic) neuropathy in a Japanese
population, involving greater dissociation of EC-SOD
from the vascular wall followed by extensive oxidative
stress and cardiac, renal, and autonomic nervous system
failure due to massive amyloid deposition [22].
In this study, we investigated whether allelic variants of
the Mn-SOD and EC-SOD genes were involved in the eti-
ology of DN in Russian type 1 diabetic patients. To do
this, we developed new methods for the simple and rapid




In this study, 88 healthy Russian donors selected at ran-
dom (59 males and 29 females, mean age 28.3 ± 8.4
years, mean ± SEM) were examined. Healthy subjects
had no autoimmune, cardiovascular, or other diseases.
All study participants lived in Moscow or the Moscow re-
gion. Blood samples were collected in the Department of
Endocrinology and Diabetology of the Russian Academy
for Advanced Medical Studies. This study was approved
by the Academy Review Board and was carried out in ac-
cordance with the principles of the second Helsinki Dec-
laration. Informed consent was obtained from all
subjects before participation in this study.
We studued a total of 166 genetically unrelated Russian
patients affected with type 1 diabetes mellitus (97 males
and 69 females, mean age 25.0 ± 13.4 years, mean dura-
tion of diabetes 9.6 ± 9.2 years). None of the patients
studied were treated with antioxidants. Patients with
causes of neuropathy other than diabetes (e.g. chronic al-
cohol abuse, drug-induced neuropathy), truncal neurop-
athy, and significant neurological diseases (e.g.
Parkinson's disease, epilepsy, multiple sclerosis) were
excluded from the association study. DN was diagnosed
on the basis of symptomatic symmetrical distal neuropa-
thy (reduced/absent ankle reflexes, reduced vibration,
thermal, tactile, pin-prick, and/or position sensation)
with one or more typical symptoms (burning pains or
cramps, paresthesiae, numbness) of at least moderate
severity in the feet. DN patients were also identified by
measuring the motor conduction velocity of the peroneal
nerve, with a velocity of <42 m/s (mean 31.6 ± 1.0 m/s)
used to identify patients with DN. Accompanying retin-
opathy was diagnosed based on the presense of microan-
eurysms together with hard exudates and retinal
hemorrhages, new vessel formation and/or fibrous reti-
niis proliferans Clinical nephropathy was diagnosed on
basis of persistent proteinuria (urinary protein excretion
rate >0.3 g/24 h). The 166 patients tested were assigned
to two groups according to the duration of diabetes. The
groups were formed using principal of extreme pheno-
type and nonoverlapping selection criteria to minimize
the masking effects of non-genetic factors. The first
group consisted of 82 patients with diabetes of short du-
ration (<3 years) and DN. The other group contsisted of
the remaining 84 diabetic patients, all of whom had dia-
betes of long duration (>10 years) and no neuropathy.
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Genomic DNA isolation and genotyping of Mn-SOD
DNA was extracted from whole human blood with phe-
nol and chloroform [23]. Polymorphic regions were am-
plified by polymerase chain reaction (PCR) in 50 µl
reaction mixture consisting of 67 mM Tris-HC1 (pH 8.8),
16.7 mM ammonium chloride, 1.0 mM magnesium chlo-
ride, 0.1% Tween-20, 10% dimethyl sulfoxide, 0.2 mM of
each dNTP, 5 pmol of each primer, 100 ng of genomic
DNA, and 2.5 units of Taq polymerase (Biotekh, Russia).
To amplify the polymorphic Ala(-9)Val region, we used
primers SOD2-16F 5'-CCAGCAGGCAGCTGGCACCG-3'
and SOD2-16R 5'-TCCAGGGCGCCGTAGTCGTAGG-3'.
For the polymorphic Ile58Thr region of the Mn-SOD
gene, PCR primers SOD2-58F 5'-AAGCTCCTCCCAT-
TATCTAATAGC-3' and SOD2-58R 5'-TCAGTGCAG-
GCTGAAGAGAT-3' were used. PCR was carried out in a
PHC-2 thermal cycler (Techne, UK) with 35 cycles of de-
naturation for 1 min at 94°C, annealing for 1 min at 55°C
(Ile58Thr) or 60°C (Ala(-9)Val), and extension for 1 min
at 72°C.
To detect Ala(-9)Val dimorphism, the PCR product was
digested with BshTI. For the Ile58Thr polymorphism,
the amplified fragment was digested with Eco32I (both
enzymes from Fermentas, Lithuania). For digestion, 17
µl of PCR product, 2 µl of buffer O+/Tango™ (BshTI) or
R+/Tango™ (Eco32I) (all buffers from Fermentas,
Lithuania), and 1 µl of restriction endonuclease (1 unit/
µl) were mixed and incubated for 12 h at 37°C. Digested
DNA products were separated by electrophoresis in a 3%
agarose gel with ethidium bromide or in an 8% polyacr-
ylamide gel stained with silver [24].
Genotyping of Arg213Gly EC-SOD
The polymorphic region was amplified in a 50 µl reaction
mixture consisting of 10 mM Tris-HCl (pH 8.8), 50 mM
KCl, 1.5 mM magnesium chloride, 0.1% Tween-20, 10%
dimethyl sulfoxide, 0.2 mM of each dNTP, 5 pmol of each
primer SOD3-213F 5'-GGCTGGCCTGCTGCGTGGTGG-
3' and SOD3-213R 5'-CCTTGCACTCGCTCTCGCGCG-3',
100 ng of genomic DNA, and 2.5 units of Taq polymer-
ase. The PCR cycling profile was as described above ex-
cept that annealing was carried out for 1 min at 65°C. The
amplicon was cleaved with restriction endonuclease
Eco52I (Fermentas, Lithuania) in Eco52I+ specific buff-
er according to the manufacturer's recommendations.
Digested fragments were analyzed as described by elec-
trophoresis for the genotyping of Mn-SOD.
Table 1: Clinical characteristics of the patients
Characteristic Neuropathy No neuropathy
(n = 82) (n = 84)
Sex (male/female) 48/34 49/35
Age (years) 23.5 ± 14.3 32.1 ± 14.2
Duration of diabetes (years) 1.1 ± 0.9 20.1 ± 8.4
Glycated haemoglobin, HbA1 (%) 10.6 ± 3.0 10.8 ± 3.8
Retinopathya 31.7 92.8
Nephropathya 2.4 59.5
Values are mean ± SEM or a percentage of patients
Figure 1
Restriction analysis of Ala(-9)Val polymorphism in the SOD2 gene. Lanes 2-14: 13 samples after digestion with BshTI; lanes 2, 3,
5, 8, and 10, Ala/Ala genotype; lanes 4, 7, 9, 12, and 14, Ala/Val genotype; lanes 6, 11, and 13, Val/Val genotype. Lanes 1 and 15:
molecular weight DNA marker φX174/HinfI 100-, 82- and 60-bp DNA fragments are shown.
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Genotype frequencies were checked for deviation from
Hardy-Weinberg equilibrium by the Χ2 and G-statistic
tests, using the Rows and Columns program based on the
Roff and Bentzen algorithm [25]. Genotype and allele
frequencies in the groups studied were compared by
Fisher's exact test The p value was corrected by multiply-
ing it by the number of alleles (2) for each locus to obtain
the p
c
 value. Odds ratios and 95% confidence interval
(95% CI) were calculated to assess the strength of the re-
lationship between the Mn-SOD or EC-SOD polymor-
phisms and DN.
Results
The Ala(-9) Val polymorphism of the Mn-SOD gene
The first adenosine residue from 3'end of the forward
primer, SOD2-16F, is mismatched with genomic DNA.
The original sequence, near the polymorphic site of the
Mn-SOD gene, is 5'-TCCGGT-3' with the most variable 3'
thymidine (Val) to cytidine (Ala) at position -9 [26]. Use
of the mismatched primer, SOD2-16F, results in a 91-bp
PCR product. This product may or may not contain a
BshTI restriction site (5'-ACCGGT-3'), depending on the
sequence. If the -9 codon is GTT (Val), than digestion
with BshTI produces two DNA fragments, 17 and 74 bp in
length. If codon -9 is GCT (Ala), the amplified product
not digested with this enzyme (Fig. 1).
The Ala allele and the Ala/Val genotype were the most
common in healthy subjects (Table 2). The observed lev-
el of heterozygosity was 53.4%. The observed genotype
frequency was consistent with Hardy-Weinberg equilib-
rium Χ2 = 2.0976 and G-statistic = 2.1149, p = 0.3930 ±
0.0154).
The frequencies of the Ala allele and the Ala/Ala geno-
type were significantly lower in patients with DN than in
patients without DN whereas the frequency of the Val al-
lele and the homozygous Val/Val genotype was signifi-
cantly higher in patients with DN (Table 3).This suggests
that the Ala(-9)Val dimorphism in the Mn-SOD gene is
associated with neuropathy in type 1 diabetes mellitus.
The Ala allele (odds ratio = 0.48, 95% CI; 0.31-0.74) and
the Ala/Ala genotype (odds ratio = 0.34, 95% CI; 0.17-
0.66) are associated with lower risk of DN development
in than the Val allele (odds ratio = 2.09, 95% CI; 1.35-
3.24) and the Val/Val genotype (odds ratio = 5.10, 95%
CI; 1.77-14.69).
Table 2: Allele and genotype distribution of the Ala(-9)Val Mn-
SOD and Arg213Gly EC-SOD polymorphic markers in healthy 
subjects
Ala(-9)Val Frequency Arg213Gly Frequency
Mn-SOD n (%) EC-SOD n (%)
Allele distribution
Ala 119(67.6) Arg 116(65.9)
Val 57 (32.4) Gly 60(34.1)
Genotype distribution
Ala/Ala 36 (40.9) Arg/Arg 34 (38.6)
Ala/Val 47 (53.4) Arg/Gly 48 (54.5)
Val./Val 5 (5.7) Gly/Gly 6 (6.8)
Table 3: Allele and genotype distribution of the Ala(-9)Val Mn-SOD polymorphic marker in type 1 diabetic patients with and without 
neuropathy
Group Allele frequency Genotype frequency
n(%) n (%)
Ala Val Ala/Ala Ala/Val Val/Val
Neuropathy 83 a 81 b 14c 55 13d
(n = 82) (50.6) (49.4) (17.1) (67.0) (15.9)
No neuropathy 115 53 33 49 2
(n = 84) (68.5) (31.5) (39.3) (58.3) (2.4)
a Ala allele frequency was significantly lower in patients with diabetic neuropathy than in subjects without this complication (odds ratio = 0.48, p= 
0.00067, pc = 0.00134). 
b Val allele frequency was significantly higher in patients with diabetic neuropathy than in subjects without this complication 
(odds ratio = 2.10, p= 0.00067, pc = 0.00134). 
c Ala/Ala genotype frequency was significantly lower in patients with diabetic neuropathy than in sub-
jects without this complication (odds ratio = 0.34, p = 0.00122, pc = 0.00366). 
d Val/Val genotype frequency was significantly higher in patients with 
diabetic neuropathy tha in subjects without this complication (odds ratio = 5.10, p = 0.00219, pc = 0.00657).
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The penultimate adenosine residue at 3' end of the re-
verse primer SOD2-58R used is not complemetary to the
genomic sequence (5'-GATAGC-3'), creating an Eco32I
restriction site (5'-GATATC-3') during amplification if
codon 58 is ATA (Ile) [26]. In this case, a 140-bp PCR
product is produced, which yields two fragments, 20-bp
and 120-bp in size, on digestion with Eco32I. If codon 58
is ACA (Thr allele) the amplified product not cleaved by
this enzyme.
Eighty-seven of the 88 healthy subjects displayed the Ile/
Ile genotype, the remaining subject was heterozygous,
Ile/Thr. All of the diabetic patients without complica-
tions were homozygous (Ile/Ile), as were all but one of
the patients with DN, the remaining patient being heter-
ozygous. So, no association between the Ile58Thr poly-
morphism of the Mn-SOD gene and DN was observed in
type 1 diabetic patients.
The Arg213 Gly polymorphism of the EC-SOD gene
The last guanosine residue at the 3' end of the reverse
primer, SOD3-231R, displays a mismatch with the origi-
nal sequence, 5'-CGGCGG-3', close to codon 213 of the
EC-SOD gene. This resulted (depending on the se-
quence) in creation of an Eco52I restriction site (5'-CG-
GCCG-3') in the PCR product [19]. If codon 213 was CGG
(Arg), a 104-bp PCR product was obtained that yielded
two DNA fragments of 23 and 81 bp in size on digestion
with Eco52I. In contrast, if codon 213 was GGG (the Gly
allele), the 104-bp product was not digested with the en-
zyme (Fig. 2).
The Arg allele was 1.9 times more frequent than the Gly
allele in healthy subjects. Arg/Arg homozygotes were 5.7
times more frequent than Gly/Gly homozygotes (Table
2). The observed level of heterozygosity was 54.6%. The
observed genotype distribution was consisted with Har-
dy-Weinberg equilibrium (Χ2 = 1.9495 and G-statistic =
1.9614, p = 0.3980 ± 0.0155). No significant difference in
allele and genotype distribution was found between DN
patients and patients without DN (Table 4). Thus,
Arg213Gly substitution in the EC-SOD gene is not asso-
ciated with nerve lesions in type 1 diabetes mellitus.
Discussion and Conclusions
A number of techniques have been described for detec-
tion of the Ala (-9)Val Mn-SOD gene dimorphism. One
such method is PCR amplification of the polymorphic re-
gion, followed by BsaWI treatment (i.e., PCR/restriction
fragment length polymorphism, PCR/RFLP) [16]. An-
other method is single-strand conformational polymor-
phism (SSCP) analysis of the product amplified by PCR
[9]. A third method is two-step PCR using allele-specific
primers for a second round of PCR [10]. Finally, the PCR
product can be hybridized with allele-specific oligonucle-
otide (ASO) probes [13]. We have decided to use restric-
tion endonuclease BshTI for detection of the Ala(-9)Val
polymorphism because this enzyme is commercially
available in Russia whereas BsaWI is not. Our detection
method has advantages over other techniques because is
Table 4: Allele and genotype distribution of the Arg213Gly Mn-SOD polymorphic marker in type 1 diabetic patients with and without 
neuropathy
Group Allele frequency Genotype frequency
n(%) n (%)
Arg Gly Arg/Arg Arg/Gly Gly/Gly
Neuropathy 82 82 16 50 16
(n = 82) (50.0) (50.0) (19.5) (61.0) (19.5)
No neuropathy 95 73 21 53 10
(n = 84) (56.5) (43.5) (25.0) (63.1) (11.9)
Figure 2
Restriction analysis of Arg213Gly polymorphism at the
SOD3 gene. Lanes 1-3, 5-12: 11 samples after digestion with
Eco521; lanes 3, 7, and 11, Arg/Arg genotype; lanes 1, 2, 8, 10,
and 12, Arg/Gly genotype; lanes 5, 6, and 9, Gly/Gly geno-
type. Lane 4: molecular weight DNA marker pBR322/MspI
90- and 76-bp DNA fragments are shown.
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borious procedure of SSCP analysis after PCR amplifica-
tion. Our molecular assay involves use of the mismatch-
PCR/RFLP approach, which can be applied to the detec-
tion of any polymorphic single base substitution that
fails to create or eliminates restriction sites. This rapid
assay requires no special equipment or expertise. The
use of a mismatch PCR primer makes it possible to create
a restriction site in the amplified product only in the
presence of the polymorphic base. This approach has
been used to genotype the M235T variant of angi-
otensinogen [27] and the C1166T nucleotide variation in
the angiotensinogen II (type 1) receptor gene [28].
The Ala allele of the Mn-SOD gene was more widespread
than the Gly allele in healthy Russian subjects. This fea-
ture is common to all other Caucasian population sam-
ples tested (Germans, Swedes, Lithuanians, Finns, and
Saamis) [16, 29]. In contrast, the frequency of the Ala
variant is significantly lower in Asian populations (Chi-
nese and Japanese) than in most European populations
[9, 11, 13, 29].
The Ala/Val variation in the Mn-SOD leader signal af-
fects the processing efficiency of the enzyme. The confor-
mations of the Ala-type and Val-type leader signals have
been predicted: the Ala form has an alpha-helical struc-
ture, a common conformation for mitochondrial leader
signals, whereas the Val form may change its conforma-
tion from alpha-helix to beta-sheet starting from the po-
sition 16 due to amino acid substitution [9]. The Val form
is less efficiently transported into mitochondria than the
Ala form of the enzyme [9]. Poor signal sequence recog-
nition by a receptor in the inner mitochondrial mem-
brane may result in mistargeting. In addition, inefficient
cleavage of a particular signal may reduce the level of en-
zymatic activity of an imported protein, such as Mn-
SOD, within the mitochondrial compartment [30]. Stud-
ies of processing have suggested basal level of the Mn-
SOD activity may be highest for Ala/Ala, followed by Ala/
Val, and then Val/Val [13].
The Val variant of the Mn-SOD may be present in a lower
concentration in mitochondria. If this is the case, then
homozygous Val/Val should have lower resistance to ox-
idative stress than patients with other Mn-SOD variants.
Such lower resistance is a common feuature of diabetes
mellitus and various ageing and neurological disorders.
This study showed that the Val Mn-SOD allele predis-
posed patients to the development of DN in type 1 diabe-
tes mellitus. Inefficient targeting of Mn-SOD may leave
mitochondria inabequately defended against superoxide
radicals. This may lead to protein oxidation, mitochon-
drial DNA mutations and damage, common in the patho-
genesis of diabetic neuropathy [2, 3] and
neurodegenerative disorders such as Alzheimer and Par-
kinson's disease [31].
The Ala/Val dimorphic site is located within exon 2 of the
Mn-SOD gene. Knock-out mice lacking exons 1 and 2 of
Mn-SOD have been found to display progressive motor
disturbances due to neuronal degeneration [32]. This ob-
servation provides future evidence for the involvement
of the SOD2 gene in neuropathology.
Another functional polymorphism of the Mn-SOD gene,
Ile58Thr in exon 3, affects the stability of the Mn-SOD
tetramer and reduces the activity of the enzyme [14].
However, the Thr allele has been shown to be extremely
rare. Our data consistent with those of Grasbon-Frodl et
al. [16] who detected the Ile/Ile variant in only 63 ran-
domly selected German subjects. The Ile58Thr variation
of Mn-SOD probably not involved in DN pathogenesis.
However this mutation is more likely to be involve in he-
reditary aging-related neurodegenerative disease, as
shown by the finding that leukocytes lose the ability to
induce Mn-SOD expression in response to increases in
reactive oxygen species levels in tissue, in subjects over
the age of 55 years [14]. Thus, older people with genetic
defects in the four-helix bundle tetrameric interface of
Mn-SOD may be especially prone to degenerative diseas-
es.
An Arg213Gly substitution in the extracellular isoform
(EC-SOD) does not affect enzymatic activity but does af-
fect the amount of the enzyme on the external endotheli-
al cell surface [33]. The Arg variant of EC-SOD is the
most common in varios populations [17, 18] including
the Russian population (Table 2). Arginine-to-glycine
substitution occurs in the center of the carboxyl-terminal
cluster of positively charged amino acid residues defin-
ing the heparin-binding domain [17]. This amino acid
substitution results in a higher level of dissociation of the
enzyme from the cell surface into serum. Thus, the lower
levels of EC-SOD on vascular walls must be positively
correlated with a higher risk of progression of oxidative
stress in affected patients with the Gly/Gly genotype.
However, this finding was not supported by our data
which showed a lack of association of the polymorphic
marker with diabetic neuropathy. Such a relationship
has been found only in Japanese patients with non-dia-
betic form of neuropathy resulting from massive amyloid
deposition in nervous tissues [22].
Finally, we have no comparative data concerning the role
of genetic factors directly related to oxidative stress in
DN formation and progression. It would be of value to
compare our findings with those of similar association
studies in other populations.
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